Latest Headlines

Latest Headlines

Pfizer joins a powerhouse syndicate backing $43M round for Nimbus

After years of careful preclinical foundation work, Nimbus Therapeutics has added another marquee name to its Big Pharma-heavy list of backers and put together a $43 million B round that will put its computer-driven drug design technology to the clinical test in one of the hottest fields in biotech.

The 2013 Fierce 15 biotech execs take a bow

Our annual Fierce 15 report on a top class of up-and-coming private biotechs came out today and I wanted to highlight the responses from many of the companies which are on the list. Read more | Check out this year's report

FierceBiotech's 2013 Fierce 15

Last year when Ryan McBride and I were sorting through our short list of candidates, we both felt that Seaside Therapeutics deserved a spot on the list. The small company had raised a considerable...

Shire strikes discovery deal in rare diseases with Bill Gates-backed Nimbus

Shire has nailed down another deal to fuel its growing rare disease unit. The pharma group has tapped the Cambridge, MA-based startup Nimbus Discovery, which will use its computational approach to find small-molecule drugs for rare genetic diseases known as lysosomal storage disorders.

Ex-ImClone boss takes top job at Bill Gates-backed startup

Dan Lynch, the former CEO and financial chief of ImClone Systems (acquired by Eli Lilly), has taken the executive chairman job at the Cambridge, MA-based biotech startup Nimbus Discovery.

Biotechs reinvent from the ground up to build value

As biotechs face monumental funding challenges and a stingy IPO market, young companies are investing in business models that have the potential to maximize the value of their drug candidates.

Nimbus will use $24M round to create a new biotech model

A little biotech start-up in Cambridge, MA with big plans for computational drug discovery work has lined up a $24 million A round with the help of some high-profile investors, including Microsoft's

Bill Gates backs fledgling computational drug discovery upstart

Bill Gates has invested a small part of his personal fortune and professional reputation in a Cambridge, MA-based startup that is promising to use cutting-edge computational technology to identify